- 3D printed mouthguard developed by Australian medical device company Oventus
- Clinically proven to reduce or alleviate snoring*
- Innovative design incorporates an additional airway that directs air to the back of the throat
A ground-breaking medical mouthguard invented by a Queensland dentist is poised to take on the multi-billion dollar world sleep disorder market.
Sleep disorders such as sleep apnoea and snoring have been linked to workplace accidents and chronic health conditions such as high blood pressure, stroke, irregular heartbeats and diabetes.
The most common treatment for sleep disordered breathing is Continuous Positive Airway Pressure (CPAP) which requires patients to wear a face or nasal mask during sleep. The mask, connected to a pump, provides a positive flow of air into the nasal passages in order to keep the airway open.
Oventus clinical director and founder Dr Chris Hart said many sufferers using CPAP appliances experience major side effects including dry throat, sore throat, dry nose, irritation to the face from the mask, claustrophobia or nasal obstruction which stops many of them wearing their device.
To counter this, Oventus devised an oral mouthguard that incorporated an airway that directs air to the back of the throat to increase airflow and bypass obstructions of the nose, tongue and soft palate. The device, a 3D-printed titanium mouthguard, is custom-made to fit individual sufferers rather than a one-size fits all approach.
“As a sleep apnoea sufferer myself, I knew there had to be a better alternative that could increase airflow past the soft palate and tongue, that had fewer side effects,” said Dr Hart.
The device is listed on the Australian Register of Therapeutic Goods (ARTG) with the Therapeutic Goods Administration (TGA) in Australia and is currently on the market. In April 2016, the device received FDA 510k clearance, further validating the technology as it prepares to target the $20 billion global sleep disordered breathing market.
According to a 2010 Deloitte Access Economics** report an estimated 1.5 million Australians suffer with sleep disorders, and more than half of these suffer from Obstructive Sleep Apnoea (OSA).
A recent clinical study* in Australia showed the device successfully eliminated snoring completely in 82 per cent of patients and significantly reduced it in all 100 per cent of patients. The study also showed positive results in those people who had nasal obstructions and mainly breathed through their mouths, including when they were asleep.
“The recent clinical data strongly supports its superior performance and clearly demonstrates its effectiveness in treating a range of sleep disorders,” said Dr Hart.
“It also shows improved oxygen levels for patients and it means that a greater number of patients who are CPAP intolerant or mild to moderate sufferers of sleep apnoea now have an alternative treatment option available.”
If you’re interested in finding out more about Oventus you can register online at http://oventus.com.au/patient-registration/
** Deloitte Access Economics. Reawakening Australia: the economic cost of sleep disorders in Australia, 2010. Canberra, Australia.
*Oventus clinical trial data on file.